|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2009-9-21
|
|
pubmed:abstractText |
Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitabine versus taxanes.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1369-6998
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
238-45
|
|
pubmed:meshHeading |
pubmed-meshheading:19732030-Administration, Oral,
pubmed-meshheading:19732030-Antimetabolites, Antineoplastic,
pubmed-meshheading:19732030-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19732030-Breast Neoplasms,
pubmed-meshheading:19732030-Deoxycytidine,
pubmed-meshheading:19732030-Drug Costs,
pubmed-meshheading:19732030-Female,
pubmed-meshheading:19732030-Fluorouracil,
pubmed-meshheading:19732030-Humans,
pubmed-meshheading:19732030-Infusions, Intravenous,
pubmed-meshheading:19732030-Linear Models,
pubmed-meshheading:19732030-Middle Aged,
pubmed-meshheading:19732030-SEER Program,
pubmed-meshheading:19732030-Taxoids
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
|
|
pubmed:affiliation |
Department of Health Evaluation Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|
